• HPAPI
  and cytotoxic drugs contract manufacturing market is projected to reach USD 25
  billion by 2030

• 
  

• Growing
  at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract
  manufacturing market is projected to reach USD 25 billion by 2030, claims Roots
  Analysis

Fragment-Based
Drug Discovery Market is estimated to be worth around USD 1.6 billion by 2030,
predicts Roots Analysis

Roots
Analysis is pleased to announce the publication of its recent study, titled, “Fragment-based Drug Discovery Market: Library and Service Providers,
2020-2030.”

Roots
Analysis has done a detailed study on Ophthalmic Drugs Contract Manufacturing
Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms
(Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments,
Suspensions, and Tablets / Capsules), 2020-2030, covering key aspects of the
industry’s evolution and identifying potential future growth opportunities.

Oligonucleotide
Synthesis, Modification and Purification Services Market is estimated to be
worth USD 5.8 billion in 2030, predicts Roots Analysis

Neoantigen
Targeted Therapies Market is estimated to be worth USD 3 Billion in 2030,
predicts Roots Analysis

Roots
Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint
Inhibitors and Stimulators Market,
2020-2030.” 

The
report features an extensive study of the current market landscape, offering an
informed opinion on the likely adoption of these therapies over the next
decade. It features an in-depth analysis, highlighting the capabilities of
various stakeholders engaged in this domain. In addition to other elements, the
study includes:

·       
A detailed assessment of the current market
landscape of drug developers engaged in the development of next generation
immune checkpoint modulators.

·       
A detailed analysis of more than 590
completed, ongoing and planned clinical studies of next generation immune
checkpoint inhibitors and stimulators.

·       
Detailed profiles of developers of next
generation immune checkpoint modulators (shortlisted on the basis of the number
of pipeline products).

·       
An in-depth analysis of more than 490 grants
that have been awarded to research institutes engaged in next generation immune
checkpoint therapy-related projects.

·       
An analysis of the partnerships that have
been established in this domain, in the recent past.

·       
A competitiveness analysis of biological
targets, featuring insightful pictorial summaries and representations.

·       
An analysis of the initiatives of big
biopharma players engaged in this domain.

A
detailed market forecast, featuring analysis of the current and projected
future opportunity across key market segments (listed below)

Recent
advances in the manufacturing technologies have prompted pharmaceutical
companies to consider shifting from the traditional multi-step, batch
manufacturing processes to faster, and relatively more efficient continuous
manufacturing

Roots
Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market, 2021-2030.” 

The
report features an extensive study of the current market landscape and future
opportunities associated with cell therapy manufacturing. It focuses on both
contract manufacturers, as well as developers with in-house manufacturing
facilities, offering in-depth analyses of the various business entities that
are engaged in this domain, across different global regions. Amongst other
elements, the report includes:

·       
An analysis of the various expansion
initiatives undertaken by service providers, in order to augment their
respective cell therapy manufacturing capabilities, over the period 2015-2019.

·       
An analysis of the recent partnerships
focused on the manufacturing of cell-based therapies, which have been
established in the period 2014-2019.

·       
Informed estimates of the annual commercial
and clinical demand for cell therapies, in terms of number of cells produced
and area dedicated to manufacturing.

·       
An estimate of the overall, installed capacity
for manufacturing cell-based therapies based on information reported by
industry stakeholders in the public domain A competitiveness analysis of
biological targets, featuring insightful pictorial summaries and
representations.

·       
A detailed analysis of the various factors
that are likely to influence the pricing of cell-based therapies, featuring
different models / approaches that may be adopted by manufacturers while
deciding the prices of their proprietary offerings.

·       
A qualitative analysis, highlighting the
various factors that need to be taken into consideration by cell therapy
developers while deciding whether to manufacture their respective products
in-house or engage the services of a CMO.

·       
An elaborate discussion on the role of
automation technologies in improving current manufacturing methods.

·       
A discussion on cell therapy manufacturing
regulations across various geographies, including North America, Europe, and
Asia Pacific.

·       
Elaborate profiles of key players (industry
and non-industry) that offer contract manufacturing services.

·       
A discussion on affiliated trends, key
drivers and challenges, which are likely to impact the industry’s evolution,
under a comprehensive SWOT framework.

Get Detailed
Market Analysis:

https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html